Project Grant R21HL181551
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $322K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Peca Labs Inc. to develop a novel, fully-polymeric, biomimetic prosthetic mitral valve. The objective is to create a valve that combines the positive characteristics of both biological and mechanical mitral valves to improve durability, performance, and patient outcomes. Peca Labs will subject the polymer leaflet material to hydrodynamic...
- The $784,203 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting the development and testing of a small, durable, and hemocompatible centrifugal blood pump for use in children aged 1-11 years (weighing approximately 10-35 kg) with heart failure. The immediate goal is to test and refine the "PSU Child VAD" (ventricular assist device) prototype through a series of 30-day in-vivo studies to validate the design...
- The National Heart Lung and Blood Institute awarded a $414,982 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville Division, Office of Research & Sponsored Programs. The grant aims to enhance a surgical planning tool for heart valve procedures by developing a force-validated computational model of the mitral valve using experimental data from both healthy porcine and human valves. This research will improve the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $709,718 Project Grant to Florida International University (FIU) on September 1, 2025. The objective of this award is to develop methods for storing and preserving living valvular allografts (tissue transplants) ex vivo, to maintain their viability and availability for cardiac valve transplantation procedures. The project aims to integrate a preservation solution...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding the development of a "Fail Safe, High Output Failing Fontan Pump" to provide mechanical circulatory support for individuals with congenital heart disease and single ventricle physiology. The $320,838 award to Perfusion Solutions Inc. (UEI: TF8CUC65VLG5) supports the hydraulic design refinement and component development of a...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $742,323 to Vanderbilt University to develop a new bioprosthetic aortic valve made from the pulmonary visceral pleura (PVP) tissue. The research aims to demonstrate the PVP valve's superior mechanical durability, calcification resistance, and hemodynamic performance compared to current bioprosthetic valves, in order to improve the long-term durability of...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
This $321,679 Project Grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and testing of an expandable pediatric pulmonary heart valve device. The research aims to create a valve that can grow larger with the patient to address the challenge of multiple open-heart surgeries required for infants and children with severe heart valve defects. The key research activities include optimizing the stent design and evaluating the valve device in a juvenile pig model. The grant was awarded to Aptus, LLC, a small business, to conduct this work over the period from September 1, 2025 to August 31, 2027.
Generated 10/21/25, 6:02 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $321.7k | 8/29/25 |